About a month after launching Heplisav-B in the U.S., Dynavax just nabbed unanimous recommendation from a CDC expert panel for the hepatitis B vaccine. Through an agreement with CRG LP, Dynavax could receive up to $175 million in a loan to support the vaccine’s commercialization.Original Article
Dynavax secures $175M to fuel Heplisav-B marketing, immuno-oncology trials
